|
|
|
Recombinant Antibodies for Cancer Therapy: Reviews and Protocols |
|
|
|
|
¡Ø±³È¯ ¹× ¹ÝÇ°¾È³» :
- ±³È¯À̳ª ¹ÝÇ°½Ã »óÇ° ¼ö·ÉÈÄ 3ÀÏÀ̳» ±³È¯À̳ª ¹ÝÇ° Àǻ縦 ¾Ë·ÁÁֽðí ÀÏÁÖÀÏÀ̳»¿¡ ÀúÈñÂÊÀ¸·Î »óÇ°ÀÌ ÀÔ°íµÇ¾î¾ßÇÕ´Ï´Ù. ½ÃÀÏÀÌ °æ°úµÇ¸é ¹ÝÇ°ÀÌ ºÒ°¡ÇÕ´Ï´Ù. - º¯½É¿¡ ÀÇÇÑ ±³È¯À̳ª ¹ÝÇ°½Ã, ¹è¼Ûºñ´Â °í°´´Ô²²¼ ºÎ´ãÇϽøç, ¿À¹è¼ÛÀ̳ª »óÇ° ºÒ·®½Ã¿¡´Â ¹«·á ±³È¯ÀÌ °¡´ÉÇÕ´Ï´Ù. - ¹ÝÇ°½Ã¿¡´Â ¹ÝÇ°»óÇ° °Ë¼öÈÄ Ä«µå Ãë¼Ò¸¦ Çص帮°Å³ª ÅëÀå,Àû¸³±ÝµîÀ¸·Î ȯºÒ Á¶Ä¡ ÇØ µå¸³´Ï´Ù. |
|
¡Ø¹è¼Û¾È³» :
- Á¦ÁÖµµ¹× µµ¼»ê°£Áö¿ªÀº Åùèºñ°¡ Ãß°¡µÉ¼ö ÀÖ½À´Ï´Ù. |
|
|
|
|
|
|
|
|
|
From Book News, Inc. After reviewing the current status of recombinant antibodies in cancer therapy, specialists provide detailed laboratory protocols for hybridoma-derived recombinant antibodies, recombinant antibody fragments from phagemid-displayed antibody repertoires, antibody fragments with additional properties, and the large-scale production of recombinant antibodies for clinical applications. The procedures have been successfully verified, and are described step-by-step, with a troubleshooting guide appended. The focus is on therapeutic agents for cancer patients. The intended readers are primarily scientists working on recombinant antibodies, but also clinicians involved with antibody-based therapies.Book News, Inc., Portland, OR
Book Info Axaron Bioscience AG Heidelberg, Germany. Presents a survey of the current status of engineered antibodies and describes in detail many readily reproducible methods of generating the novel and promising antibody-based reagents of today's cancer therapy. DNLM: Antibodies--therapeutic use.
|
|
|
|
|
|
|
|
|
|
|
µî·ÏµÈ ¼ÆòÀÌ ¾ø½À´Ï´Ù. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|